Sai Parenteral's IPO

Sai Parenteral's IPO is listed on BSE and NSE, priced at ₹372–₹392 per share. The stock debuted at ₹400, delivering a listing gain of 2.0%. The IPO had a lot size of ₹38 shares and a minimum investment of ₹14,896.

Sai Parenteral's Limited IPO

Mainboard Listed
₹14,896 (38 Shares)
Minimum Investment
Check Allotment
IPO Dates
Mar 24, 2026 – Mar 27, 2026
Price band
₹372-392 per equity share
Minimum Investment
₹14,896
Issue size
₹408.79 Cr
Lot size
38
Allotment Date
Mar 30, 2026
Listing
Apr 2, 2026
Listing At
BSE, NSE

IPO timeline

  1. Mar 24, 2026

    Open Date

    Completed

  2. Mar 27, 2026

    Close Date

    Completed

  3. Mar 30, 2026

    Allotment Date

    Completed

  4. Apr 2, 2026

    Listing Date

    Completed

Price Summary

Last closing
488.00 (24.49%)
52 week high
526.30
52 week low
400.00
Last update

Sai Parenteral's IPO Subscription Details

View Subscription Details
QIB 1.73x
Retail 0.12x
NIIs 2.45x
bHNI 3.56x
sHNI 0.24x
Retail 0.12x
Total 1.08x

Sai Parenteral's IPO subscription status shows demand across QIB, NII, and retail categories, helping investors understand participation levels.

Last updated:

Sai Parenteral's IPO Essentials

Sai Parenteral's IPO Details

Sai Parenteral's IPO is priced at ₹372-392 per share with a total issue size of 408.79 crore. The IPO has a lot size of 38 shares and is listed on a BSE and NSE.

Issue price
₹372-392 per equity share
Lot size
38 shares
Face value
₹5 Per Equity Share
Issue size
₹408.79 Crores
Total issue size
1,04,28,288 shares
(aggregating up to ₹408.79 crore)
Fresh issue
72,70,408 shares
(aggregating up to ₹285 crore)
Offer for sale (OFS)
31,57,880 shares
(aggregating up to ₹123.79 crore)
Listing at
BSE, NSE
List price
400.0(NSE)
Listing date
Registrar
Bigshare Services Pvt.Ltd.
Lead manager
Arihant Capital Markets Ltd.

Market Lot Size

Investors can bid for a minimum of 38 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (min) 1 38 ₹14,896
Retail(max) 13 494 ₹1,93,648
sHNI(min) 14 532 ₹2,08,544
sHNI(max) 67 2,546 ₹9,98,032
sHNI(min) 68 2,584 ₹10,12,928

Sai Parenteral's IPO Documents

Sai Parenteral's IPO Reservation

Sai Parenteral's IPO reservation details show category-wise allocation of shares. Out of the total 10428288 shares, approximately 20% are reserved for QIB, 15% for NII, 35% for retail investors, and 30% for anchor investors.

Investor Category Shares Offered Maximum Allottees
Anchor Investor Shares Offered 3128485 (30%)
QIB Shares Offered 2085659 (20%)
NII (HNI) Shares Offered 1564243 (15%)
bHNI > ₹10L 1042829 (10%) 1960
sHNI < ₹10L 521414 (5%) 980
Retail Shares Offered 3649901 (35%) 96,050
Total Shares Offered 10428288 (100%)

Sai Parenteral's IPO Analytics

Sai Parenteral's IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.

Sai Parenteral's IPO Subscription Status

Sai Parenteral's IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.

The IPO is currently subscribed 1.08x, indicating moderate demand across investor categories.

As on QIB
NII
bHNI
sHNI
Retail Total
Shares Offered / Reserved 20,85,659
15,64,243
10,42,829
5,21,414
36,49,901 72,99,803
Day 1 24-03-26 05:00 PM
0.00 x
0.15x
0.22x
0.03x
0.03 x 0.05 x
Day 2 25-03-26 05:00 PM
0.60 x
1.05x
1.55x
0.04x
0.05 x 0.42 x
Day 3 27-03-26 05:00 PM
1.73 x
2.45x
3.56x
0.24x
0.12 x 1.08 x
Total No. of Applications
bHNI sHNI Retail
8166 (Approx) 0.08x 0.13x 0.08x

Sai Parenteral's Valuations

Earnings

EPS Pre IPO
₹5.43/-
P/E Pre IPO
72.19

Returns

ROE
16.82%
ROCE
28.92%
RoNW
15.09%
PAT Margin
8.88%

Fundamentals

Price / Book
10.89
Market Cap
1,731.83 Cr.

Data sourced from DRHP / RHP • For educational purposes only

Sai Parenteral's Financials( In Crs.)

30-Sep-25 31-Mar-25 31-Mar-24 31-Mar-23
Assets 376.24 272.39 268.10 133.96
Revenue 89.43 163.74 155.18 97.03
Profit After Tax 7.76 14.43 8.42 4.38
Net Worth 209.37 95.78 76.40 31.49
Reserves & Surplus 188.84 80.36 61.30 24.34
Total Borrowing 76.07 93.95 118.79 68.55

Sai Parenteral's Company & Offer Insights

About Sai Parenteral's

Established in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research and development and manufacturing.
The company has two business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
The company’s product portfolio covers a wide spectrum of pharmaceutical formulations in various therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company’s customer base comprises central and state government departments, pharmaceutical companies, public and private sector hospitals, and super stockists across India. Sai Parenteral’s started its export business in FY 2023 after acquiring two international accredited facilities in Hyderabad, Telangana, and currently serves regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, Middle East, and Africa.

The company has five manufacturing facilities in India. Four are located in Hyderabad, Telangana. These are a GMP compliant injectable facility, a WHO-GMP injectable facility, a TGA-Australia and PIC/S accredited solid oral dosage facility, and a WHO-GMP cephalosporin facility. The company’s wholly owned subsidiary has a GMP certified facility located in Ongole, Andhra Pradesh.
As of August 31, 2025, Sai Parenteral's Ltd. had 277 full-time employees.

Sai Parenteral's Promoter(s)

Anil Kumar Karusala, Vijitha Gorrepati, Karusala Aruna are the company's promoters of Sai Parenteral's.

Sai Parenteral's IPO Issue Objectives

Capacity expansion and upgradation of manufacturing facilities - ₹110.80 Crores
Establishment of a new R&D Centre - ₹18.02 Crores
Repayment / prepayment of certain outstanding borrowings - ₹14.30 Crores
Working capital requirements - ₹33.00 Crores
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) - ₹35.64 Crores
General corporate purposes

Sai Parenteral's IPO - Anchor Investors

Sai Parenterals raises Rs 123 crore via anchor book ahead of IPO.
Out of the total allocation, 9.18 lakh shares worth Rs 36 crore were allocated to one domestic mutual fund, namely Quant Mutual Fund, and 7.65 lakh shares worth Rs 30 crore to one insurance company, namely Kotak Mahindra Life Insurance Company.
Kotak Life Sciences Fund also subscribed to 7.65 lakh shares worth nearly Rs 30 crore, followed by Morgan Stanley Asia (Singapore), and India Emerging Giants Fund, which acquired 3.82 lakh shares worth Rs 15 crore and 2.96 lakh shares worth Rs 11.63 crore, respectively.

Sai Parenteral's IPO - Strengths and Risks

Sai Parenteral's IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.

Strengths

Diversified formulation portfolio with an excellent track record: The company has an established presence across several therapeutic segments and dosage forms, thus minimizing dependence on a single product category.
Strategically positioned and accredited manufacturing facilities: The WHO-GMP and international accreditations such as TGA and PIC/S for manufacturing facilities enhance credibility and provide access to regulated export markets.
Strong focus on CDMO business: The company’s CDMO business offers an opportunity for long-term contracts and high margins.

Risks

Geographical concentration of manufacturing facilities: The company’s manufacturing facilities are concentrated mainly in Telangana and Andhra Pradesh states. This creates risks of disruptions or changes in regional regulations.
Dependence on Injectable Segment: The company derives significant revenue from the Injectable Segment. Hence, it is highly vulnerable to fluctuations in demand for products from this segment.
Regulatory compliance risk: The company’s manufacturing facilities are subject to inspections and audits. Adverse observations during inspections and audits may affect business.

Contact Information

Contact Details

Sai Parenteral's

+91 79979 91301

cs@saiparenterals.com

https://saiparenterals.com

Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V. Rangareddy, Seri Lingampally, Hyderabad, Telangana - 500032.

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

ipo@bigshareonline.com

https://ipo.bigshareonline.com/ipo_status.html

Frequently Asked Questions

Click any question to reveal the answer

Sai Parenteral's IPO is a book-built IPO worth ₹408.79 crore. The price band is ₹372–₹392 per share. The IPO opens on Mar 24, 2026 and closes on Mar 27, 2026. It will be listed on BSE and NSE. Bigshare Services Pvt. Ltd. is the registrar.

The price band of Sai Parenteral's IPO is ₹372 to ₹392 per share.

The lot size of Sai Parenteral's IPO is 38 shares.

The minimum investment for Sai Parenteral's IPO is approximately ₹14,896 based on the upper price band .

Sai Parenteral's IPO opens on Mar 24, 2026 and closes on Mar 27, 2026.

The allotment date of Sai Parenteral's IPO is Mar 30, 2026.

Sai Parenteral's IPO is expected to be listed on Apr 2, 2026, on BSE and NSE .

Sai Parenteral's IPO listed on Apr 2, 2026. It was issued at ₹400.0(NSE) and is currently around ₹488.00 as on 30-Apr-2026 3:30 PM, which is approximately 24.5% versus issue price. The 52-week high is ₹526.30.

Based on listing and post-listing performance, Sai Parenteral's IPO delivered around 24.5% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.

To buy Sai Parenteral's IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.

Sai Parenteral's IPO valuation snapshot: P/E N/A, EPS ₹/-, P/B 10.89, RoNW 15.09%, and market cap 1,731.83 Cr.

To apply for Sai Parenteral's IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.

You can check the live subscription status of Sai Parenteral's IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.

Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.

If you pre-apply for Sai Parenteral's IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.

You can check Sai Parenteral's IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Sai Parenteral's IPO allotment status on IPO Ji for quick and easy access.